Biocon ranks No. 8 in ‘Global Top Employers’ by Science magazine
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Company is investing more than €100 million in the expansion of the Halle site
Subscribe To Our Newsletter & Stay Updated